Navigation Links
Continued Uptake of Novartis/Incyte's Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
Date:1/31/2013

BURLINGTON, Mass., Jan. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the continued uptake of Novartis/Incyte's recently launched JAK-2 inhibitor Jakafi (ruxolitinib) will be the greatest driver of growth in the myelofibrosis therapy market in the United States and Europe. Since only a small percentage of patients are eligible for allogeneic stem-cell transplantation—the lone curative treatment for myelofibrosis—the only care available for most patients is treatment of disease symptoms. According to interviewed experts, the entry of ruxolitinib is a significant advance in myelofibrosis treatment because they believe the drug offers clear improvements in constitutional symptoms and reduces the severe splenomegaly experienced by many patients, resulting in an overall better quality of life.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO

According to Niche Markets and Rare Diseases: Myelofibrosis, JAK-2 inhibition is the focus of considerable development activity in myelofibrosis and up to five new JAK-2 inhibitors could launch for the disease through 2021. Clinical trial data from long-term evaluation of myelofibrosis patients indicated that ruxolitinib improves overall survival in addition to providing sustained relief of constitutional symptoms—these recent analyses will likely accelerate uptake of ruxolitinib and other JAK-2 inhibitors.

"The most promising emerging JAK-2 inhibitor—YM Biosciences' CYT-387—has attracted interest from physicians because early phase trials have shown an effect on anemia in addition to an effect on constitutional symptoms," said Decision Resources Senior Vice President Cynthia Mundy , Ph.D. "Also, Gilead's recent decision to acquire YM Biosciences to gain access to the drug suggests Gilead expects CYT-387 to emerge as a formidable competitor to ruxolitinib and that this agent could capture substantial market share."

The report also finds that, although interviewed experts are enthusiastic about treatments that offer better management of myelofibrotic symptoms and improvements in quality of life, they indicate they are likely to continue using conventional treatment regimens in many of their patients, particularly those assessed as having lower risk. As a result, although ruxolitinib will experience significant adoption in the myelofibrosis market, hydroxyurea (Bristol-Myers Squibb's Hydrea, generics) will continue to be widely used to treat constitutional symptoms. Similarly, Celgene's emerging immunomodulator pomalidomide will not displace use of the older, related drugs—Celgene's Thalomid and Revlimid (lenolidomide).

About Myelofibrosis
Myelofibrosis is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
2. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
3. Anoto Announces Continued Worldwide Expansion in Healthcare
4. Education and Collaboration Key to Continued Progress in Fighting Rogue Online Prescription Drug Sellers, Reports NABP
5. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Endoscopy Devices Market to 2018 - Demand for Cost-Effective, Minimally Invasive Procedures and Reimbursement for New Indications to Increase Uptake
8. First Paralyzed Formula Race Car Drivers "Road to Indy" Sponsored By Coloplast
9. Safe Driving Prescription for Senior Drivers
10. Nedbank Golf Challenge a Driver for Breast Cancer in South Africa
11. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
(Date:4/29/2016)... , April 29, 2016 /PRNewswire/ ... Contamine, Directeur Financier Sanofi, ... santé, publie ses résultats pour le ... du Groupe, Jérôme Contamine, commente les ... et les perspectives pour le reste ...
(Date:4/28/2016)... -- Research and Markets has announced the ... 2016-2020" report to their offering.      ... global plastic surgery products market is expected to grow ... , ,The growing adoption of laser in aesthetics is ... market. Lasers are used to treat a broad range ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist ... patients can visit Dr. Assili to receive any dental extraction treatment for $40 off ... expires June 30, 2016. With the lower price, patients can more easily afford extractions ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in Orange ... decline. According to the research, which was published in the “Journal of the American ... and about 5.4 million Americans have Alzheimer’s disease. The study found that dental problems ...
(Date:5/2/2016)... ... 2016 , ... Pregnancy Awareness Month offers a great time to get familiar ... you are ready to have a baby, it’s best to get started before age ... your Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant ...
(Date:5/2/2016)... NC (PRWEB) , ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial ... listed as number five on the list of “ 5 US Cities with the Highest ... Francisco, Los Angeles, and Miami. The results were calculated using a survey by ...
(Date:5/2/2016)... FL (PRWEB) , ... May 02, 2016 , ... The ... great pain and suffering. With no cure, most patients must deal with prescription costs ... free coupon card, allowing up to 75% savings at the pharmacy on many common ...
Breaking Medicine News(10 mins):